SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AEVEX Corp. operates as a holding company. It operates through Tactical Systems and Global Solutions segments. The Tactical Systems segment focuses on design, development, and production of autonomous systems including unmanned aerial systems and unmanned surface vessels. The Global Solutions segment offers services and mission support to defense and intelligence customers. The company was founded in 2017 and is headquartered in Solana Beach, CA.

AEVEX Corp. - Ordinary Shares - Class A

AEVEX Corp. is capturing significant market attention following a strong NYSE debut that saw shares surge amid high demand for its autonomous drone and defense technology. Community discussion is focused on the company's solid government contract pipeline and the potential for momentum-driven gains, with traders actively comparing its IPO performance to other high-growth defense sector runners.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin (CRO) is seeing mixed community sentiment as investors debate its lack of correlation with Bitcoin's recent gains, leading to widespread discussion about the impact of ongoing monthly token unlocks on its price. Meanwhile, interest remains high around the potential for a U.S. exchange-traded fund, alongside active community campaigns promoting native meme coins like 'crow with knife' as a way to boost volume on the Cronos chain.

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Teva- Pharmaceutical Industries Ltd. - ADR

Teva is seeing significant market momentum driven by a strong quarterly earnings report that highlighted robust growth in its innovative drug portfolio, particularly Austedo. The community is actively discussing the stock's potential for further upside as leadership successfully executes its growth strategy and addresses long-standing debt concerns.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is facing significant downward pressure and community frustration, with many investors expressing disappointment over recent price performance and the lackluster debut of its new ETF. While some users are actively buying the dip, citing long-term potential in RWA tokenization and institutional partnerships, sentiment remains largely polarized between those betting on a future recovery and those labeling the asset a failed investment.

The Coca-Cola Co. engages in the manufacturing and marketing of non-alcoholic beverages. It operates through the following segments: Europe, Middle East and Africa, Latin America, North America, Asia Pacific, Global Ventures, and Bottling Investments. The company was founded by Asa Griggs Candler on May 8, 1886 and is headquartered in Atlanta, GA.

Coca-Cola Co

Coca-Cola remains a focal point for investors seeking defensive stability as the company navigates leadership transitions and shifting consumer preferences toward healthier alternatives. The community is actively debating the stock's valuation versus its role as a core dividend pillar, with many monitoring key technical support levels amidst broader market volatility.

American Express Co. engages in the provision of card-issuing, merchant-acquiring, and card network businesses. Its products and services include credit cards, business credit cards, corporate programs, gift cards, savings accounts and CDs, and the American Express App. It operates through the following segments: the United States Consumer Services (USCS), Commercial Services (CS), International Card Services (ICS), Global Merchant and Network Services (GMNS), and Corporate and Other. The USCS segment includes proprietary consumer cards and provides services to United States consumers. The CS segment offers corporate and small business cards and provides services to United States businesses. The ICS segment provides consumers, small businesses, and corporate cards outside the United States. The GMNS segment is involved in operating a global payments network that processes and settles card transactions, acquires merchants, and provides multi-channel marketing programs and capabilities, services and data analytics. The Corporate and Other segment covers corporate functions and certain other businesses and operations. It also operates through the following geographical segments: United States, EMEA, APAC, LACC, and Other. The EMEA segment represents Europe, the Middle East, and Africa. The APAC segment refers to Asia Pacific, Australia, and New Zealand. The LACC segment focuses on Latin America, Canada, and the Caribbean. The Other segment includes net costs which are not directly allocated to specific geographic regions. The company was founded by Henry Wells, William G. Fargo, and John Warren Butterfield on March 28, 1850 and is headquartered in New York, NY.

American Express Co.

American Express is trending following a robust Q3 earnings report that featured a revenue record and raised full-year guidance, driven by resilient spending from its affluent, premium customer base. Community members are actively debating the sustainability of this momentum, contrasting the stock's 'quality compounder' profile against broader macro volatility and increasing competition in the payments space.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing extreme volatility and rapid price surges that have captured the community's attention, with proponents highlighting upcoming music-themed events and ecosystem expansion while skeptics aggressively label the movement as a manipulated pump-and-dump scheme. The stock is heavily trending as traders debate the legitimacy of the project's ownership structure and the impact of significant short liquidations that are fueling intense speculative momentum.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending as the community debates a potential breakout above key resistance levels, fueled by optimism surrounding geopolitical developments in the Middle East and ongoing speculation regarding institutional adoption. Investors remain sharply divided, with bulls pointing to supply constraints and potential regulatory milestones, while bears emphasize technical patterns that suggest the current rally may be a temporary reprieve within a larger downtrend.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is seeing significant market chatter as investors weigh conflicting theories about potential buyout rumors against the stock's persistent trading range around $9.50. While the community remains divided over whether the stagnant price reflects institutional accumulation or continued manipulation, many are closely monitoring high volume and institutional activity as a signal for a potential breakout.

Copart, Inc. engages in the provision of online auctions and vehicle remarketing services. The firm offers vehicle sellers a full range of services to process and sell vehicles primarily over the internet through Virtual Bidding Third Generation Internet auction-style sales technology. It sells vehicles principally to licensed vehicle dismantlers, rebuilders, repair licensees, used vehicle dealers, exporters and at certain locations, and the public. The company’s services include online seller access, salvage estimation services, estimating services, end-of-life vehicle processing, virtual insured exchange, transportation services, vehicle inspection stations, on-demand reporting, DMV processing, and vehicle processing programs. It operates through the United States and International segments. The company was founded by Willis J. Johnson in 1982 and is headquartered in Dallas, TX.

Copart, Inc.

Copart is trending as investors weigh its status as a high-quality, long-term compounder against recent stock volatility and mixed quarterly results that showed a revenue miss despite earnings outperformance. The community is actively debating whether the stock's current consolidation presents a value entry point or if competitive pressures and broader shifts in the used vehicle market warrant a cautious outlook.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

KBC Group NV Boosts Position in Jazz Pharmaceuticals PLC $JAZZ

KBC Group NV boosted its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 7.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange...

Jazz Pharmaceuticals Touts Record $4.3B 2025 Revenue, Reaffirms 2026 Outlook at Conference

Jazz Pharmaceuticals (NASDAQ:JAZZ) executives highlighted record 2025 revenue, a growing pipeline anchored by oncology programs, and a refined strategy emphasizing rare diseases during a conference session featuring Chief Financial Officer Philip Johnson and investor relations leaders Jack Spinks an...

Jazz Pharmaceuticals (NASDAQ:JAZZ) Sets New 1-Year High - Time to Buy?

Jazz Pharmaceuticals (NASDAQ:JAZZ) Hits New 1-Year High - What's Next...

Jazz Pharmaceuticals PLC $JAZZ Shares Sold by State of Alaska Department of Revenue

State of Alaska Department of Revenue decreased its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 27.1% in the fourth quarter, according to its most recent filing with the...

Jazz Pharmaceuticals (NASDAQ:JAZZ) Hits New 12-Month High - Here's What Happened

Jazz Pharmaceuticals (NASDAQ:JAZZ) Reaches New 12-Month High - Still a Buy...

Jazz Pharmaceuticals to Present Research on Epidiolex (cannabidiol) and Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting

Jazz Pharmaceuticals to Present Research on Epidiolex (cannabidiol) and Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual...

Capricorn Fund Managers Ltd Purchases New Shares in Jazz Pharmaceuticals PLC $JAZZ

Capricorn Fund Managers Ltd acquired a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the...

Perpetual Ltd Lowers Stake in Jazz Pharmaceuticals PLC $JAZZ

Perpetual Ltd trimmed its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 74.3% during the fourth quarter, according to the company in its most recent 13F filing with the...

Insider Selling: Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells 6,000 Shares of Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Get Free Report) Director Bruce Cozadd sold 6,000 shares of the firm's stock in a transaction on Wednesday, April 1st. The stock was sold at an average price...

Why Is Keros Therapeutics (KROS) Up 2.5% Since Last Earnings Report?

Keros Therapeutics (KROS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Current Price	$203.42
Prev Close	$197.83
Open	$198.13
Dividend Yield	0.00%
50-Day Moving Average	$183.03
Beta	0.72
Avg. Volume	820,225.55
PE Ratio	-34.07

52-Week High	$204.13
52-Week Low	$97.50
Market Capitalization	$12.52B
EPS (Annual)	-$5.84
Price to Book	2.89
Revenue Per Employee	$1.48M

JAZZ
Jazz Pharmaceuticals plc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest JAZZ News

JAZZJazz Pharmaceuticals plc